# Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL

> **NCT07195799** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 180 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Linperlisib combined with CPT regimen
- **DRUG:** Linperlisib combined with CPT regimen
- **DRUG:** Linperlisib combined with CPT regimen
- **DRUG:** Linperlisib combined with CPT regimen
- **DRUG:** Linperlisib combined with CPT regimen
- **DRUG:** Linperlisib combined with CPT regimen

## Key facts

- **NCT ID:** NCT07195799
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07195799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07195799, "Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07195799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*